The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab before cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin: Analysis of early postoperative complication rate and long term follow-up.
Clarisse Eveno
No relevant relationships to disclose
Guillaume Passot
No relevant relationships to disclose
Diane Goéré
No relevant relationships to disclose
Philippe Soyer
No relevant relationships to disclose
Etienne Gayat
No relevant relationships to disclose
Olivier Glehen
No relevant relationships to disclose
Dominique Elias
No relevant relationships to disclose
Marc Pocard
Consultant or Advisory Role - Roche
Research Funding - Roche